{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:27:10Z","timestamp":1793456830232,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Janssen Global Services LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jns.2025.123654","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T23:18:41Z","timestamp":1755040721000},"page":"123654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Outcome measures in CIDP: A scoping and mapping review"],"prefix":"10.1016","volume":"477","author":[{"given":"Yusuf A.","family":"Rajabally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Maria","family":"Boggia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Peatman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Noel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Gary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Nobile-Orazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jns.2025.123654_bb0005","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/jnnp-2014-309697","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype","volume":"86","author":"Mathey","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"11","key":"10.1016\/j.jns.2025.123654_bb0010","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1111\/ene.14959","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision","volume":"28","author":"Van den Bergh","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2025.123654_bb0015","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1007\/s00415-017-8658-x","article-title":"Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"264","author":"Bozovic","year":"2017","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.jns.2025.123654_bb0020","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1111\/ene.15815","article-title":"Chronic inflammatory neuropathies and their impact on activities and participation","volume":"30","author":"Wonink","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2025.123654_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102512","article-title":"Clinical outcome measures in multiple sclerosis: a review","volume":"19","author":"Inojosa","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jns.2025.123654_bb0030","author":"FDA"},{"issue":"1","key":"10.1016\/j.jns.2025.123654_bb0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jns.12608","article-title":"Prognostic value of neurofilament light in blood in patients with polyneuropathy: a systematic review","volume":"29","author":"Kodal","year":"2024","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"2","key":"10.1016\/j.jns.2025.123654_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25021254","article-title":"Serum neurofilament and free light chain levels in patients undergoing treatment for chronic inflammatory demyelinating polyneuropathy","volume":"25","author":"Luigetti","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.jns.2025.123654_bb0045","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/14737175.2021.1944104","article-title":"Outcome measures and biomarkers in chronic inflammatory demyelinating polyradiculoneuropathy: from research to clinical practice","volume":"21","author":"Allen","year":"2021","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.jns.2025.123654_bb0050","author":"International consortium for health outcomes measurement (ICHOM)"},{"issue":"3","key":"10.1016\/j.jns.2025.123654_bb0055","first-page":"212","article-title":"International Consortium for JHealth Outcome Measurements (ICHOM): standardized patient-centered outcomes measurement set for heart failure patients","volume":"8","author":"Burns","year":"2020","journal-title":"Heart Failure"},{"key":"10.1016\/j.jns.2025.123654_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01645","article-title":"Standardizing health outcomes for lung cancer. Adaptation of the international consortium for health outcomes measurement set to the Spanish setting","volume":"10","author":"Escudero-Vilaplana","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.jns.2025.123654_bb0065","first-page":"1","article-title":"Fatigue in spinal muscular atrophy: a fundamental open issue","volume":"43","author":"Crisafulli","year":"2024","journal-title":"Acta Myologica"},{"issue":"5","key":"10.1016\/j.jns.2025.123654_bb0070","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s40120-023-00464-x","article-title":"Measuring overall severity of myasthenia gravis (MG): evidence for the added value of the MG symptoms PRO","volume":"12","author":"Regnault","year":"2023","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.jns.2025.123654_bb0075","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s12325-020-01540-6","article-title":"A global survey of disease burden in patients who carry a diagnosis of chronic inflammatory demyelinating polyneuropathy","volume":"38","author":"Allen","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jns.2025.123654_bb0080","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1007\/s00415-020-09998-8","article-title":"Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP)","volume":"268","author":"Querol","year":"2021","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.jns.2025.123654_bb0085","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1111\/ene.14907","article-title":"Patient perceptions of outcome measures in chronic inflammatory demyelinating polyneuropathy: a study of the inflammatory Rasch-built overall disability scale","volume":"28","author":"White","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2025.123654_bb0090","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/mus.27820","article-title":"Outcome in chronic inflammatory demyelinating polyneuropathy: A systematic review and meta-analysis","volume":"68","author":"Al-Zuhairy","year":"2023","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.jns.2025.123654_bb0095","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1468-1331.2009.02930.x","volume":"17","author":"Van den Bergh","year":"2010","journal-title":"Eur. J. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2025.123654_bb0100","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2084","article-title":"Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy","volume":"11","author":"Hayashi","year":"2021","journal-title":"Brain Behav."},{"issue":"11","key":"10.1016\/j.jns.2025.123654_bb0105","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1111\/ene.15496","article-title":"Association of plasma neurofilament light chain with disease activity in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"29","author":"Kapoor","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2025.123654_bb0110","unstructured":"Kapoor, M, Carr, A, Foiani, M, et al. Utility of Plasma Neurofilament Light Chain in Determining Subclinical Disease Activity in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. 2022128a; page 64."},{"issue":"2","key":"10.1016\/j.jns.2025.123654_bb0115","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/jns.12319","article-title":"Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy","volume":"24","author":"van Lieverloo","year":"2019","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"9","key":"10.1016\/j.jns.2025.123654_bb0120","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1111\/ene.15428","article-title":"Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies","volume":"29","author":"Kmezic","year":"2022","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2025.123654_bb0125","first-page":"351","article-title":"Neurofascin-155 CIDP patients: clinical, immunological and biomarker features","volume":"26","author":"Martin-Aguilar","year":"2021","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.jns.2025.123654_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.723009","article-title":"Calprotectin in chronic inflammatory demyelinating polyneuropathy and variants\u2014a potential novel biomarker of disease activity","volume":"12","author":"Stascheit","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2025.123654_bb0135","series-title":"Systematic Analysis of Serum Neurofilament Light Chain Levels in the CIDP01\/CIDP04 Clinical Trials","author":"Mart\u00edn-Aguilar","year":"2023"},{"key":"10.1016\/j.jns.2025.123654_bb0140","series-title":"Cerebrospinal Fluid Adenosine Triphosphate and Clinical Features in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy","author":"Hayashi","year":"2023"},{"issue":"11","key":"10.1016\/j.jns.2025.123654_bb0145","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/jnnp.2009.194324","article-title":"Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance","volume":"81","author":"Merkies","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2025.123654_bib161","doi-asserted-by":"crossref","DOI":"10.1002\/mus.28478","article-title":"Minimal Clinically Important Differences in Measuring Treatment Effects in CIDP: History, Current Use, Limitations, and Prospects","author":"Rajabally","year":"2025","journal-title":".Muscle Nerve."},{"issue":"8","key":"10.1016\/j.jns.2025.123654_bb0150","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jval.2013.08.2293","article-title":"Assessment of PRO label claims granted by the FDA as compared to the EMA (2006\u20132010)","volume":"16","author":"DeMuro","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.jns.2025.123654_bb0155","doi-asserted-by":"crossref","first-page":"S763","DOI":"10.1016\/j.jval.2019.09.1907","article-title":"PNS4 a review of perfos in FDA and EMA labelling claims (2009-2019)","volume":"22","author":"Zupan","year":"2019","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.jns.2025.123654_bb0160","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25002746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25002746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:31:36Z","timestamp":1779769896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X25002746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":33,"alternative-id":["S0022510X25002746"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2025.123654","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome measures in CIDP: A scoping and mapping review","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2025.123654","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123654"}}